Oncology · Follicular LymphomaTrial Updateclinicalmid-term

Phase II Trial of Obinutuzumab Combinations in Relapsed/Refractory Follicular Lymphoma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 12:31:31 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase II trial of obinutuzumab combinations could significantly influence treatment paradigms for relapsed or refractory follicular lymphoma. Monitoring the trial's outcomes is crucial for understanding potential shifts in clinical practice and competitive positioning in this evolving therapeutic area. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 21 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio and strategy teams should monitor the outcomes of this trial to assess potential shifts in treatment paradigms for follicular lymphoma. The strongest clinical anchor is Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov), entity match (obinutuzumab); patient population match (refractory). In Oncology · Follicular Lymphoma, 2 regulatory and 4 competitive items passed relevance filtering for Obinutuzumab.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could provide insights into new treatment combinations that may enhance efficacy in a competitive landscape where treatment options for follicular lymphoma are evolving.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). The trial outcomes may lead to new regulatory filings for combination therapies, impacting approval timelines and labeling for existing and new products in the oncology space.

Key Risks

Elevated medium regulatory exposure for Obinutuzumab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Positive trial results could enhance the market position of obinutuzumab and its combinations, potentially leading to increased revenue and market share in the oncology segment for follicular lymphoma treatments.
Upside for Obinutuzumab may improve if Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Obinutuzumab may improve if An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for Obinutuzumab may improve if Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Key milestones include trial results and any subsequent regulatory filings based on the findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ClinicalTrials.govhigh relevance
Entity match (obinutuzumab); Patient population match (refractory)
FDA document
View source
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
ClinicalTrials.govhigh relevance
Entity match (lenalidomide); Patient population match (refractory)
FDA document
View source
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (refractory)
FDA document
View source
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
ClinicalTrials.govmedium relevance
Patient population match (refractory)
FDA document
View source
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.govmedium relevance
Patient population match (refractory)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Brentuximab vedotin shows effectiveness over standard chemotherapy in relapsed Hodgkin lymphoma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedhigh relevance
Entity match (lenalidomide); Patient population match (refractory)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Obinutuzumab
Umbralisib
Lenalidomide
National Cancer Institute

Commercial impact

medium

Positive trial results could enhance the market position of obinutuzumab and its combinations, potentially leading to increased revenue and market share in the oncology segment for follicular lymphoma treatments.

Regulatory impact

medium

The trial outcomes may lead to new regulatory filings for combination therapies, impacting approval timelines and labeling for existing and new products in the oncology space.

What to watch

Key milestones include trial results and any subsequent regulatory filings based on the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.